Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jen-Chung Ko

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Oncotarget|November 23, 2017
Real-world experience of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinomaSheng-Kai Liang, Min-Shu Hsieh, Meng-Rui Lee, et al.
International Journal of Antimicrobial Agents|April 11, 2014
Bacteraemia caused by Mycobacterium abscessus subsp. abscessus and M. abscessus subsp. bolletii: clinical features and susceptibilities of the isolatesMeng-Rui Lee, Jen-Chung Ko, Sheng-Kai Liang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 23, 2009
The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cellsJen-Chung Ko, Lyu-Han Wang, Jhih-Yuan Jhan, et al.
Cancer Medicine|June 23, 2017
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in TaiwanChia-Hao Chang, Chih-Hsin Lee, Jen-Chung Ko, et al.
Toxicology Research|June 5, 2019
Capsaicin enhances erlotinib-induced cytotoxicity <i>via</i> AKT inactivation and excision repair cross-complementary 1 (ERCC1) down-regulation in human lung cancer cellsJyh-Cheng Chen, Jen-Chung Ko, Ting-Chuan Yen, et al.
Biochemical Pharmacology|December 21, 2010
Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabineJen-Chung Ko, Min-Shao Tsai, Ya-Hsun Kuo, et al.
BMC Cancer|November 9, 2016
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cellsChun-Hao Pan, Ying-Fang Chang, Ming-Shuo Lee, et al.
Biochemical Pharmacology|October 6, 2009
Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cellsJen-Chung Ko, Ying-Jhen Su, Szu-Ting Lin, et al.
Pharmacology|November 17, 2020
Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer CellsJyh-Cheng Chen, Jen-Chung Ko, Yong-Cing Taso, et al.
Biochemical Pharmacology|February 28, 2016
Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cellsJen-Chung Ko, Jyh-Cheng Chen, Tai-Jing Wang, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Oncotarget|November 23, 2017
Real-world experience of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinomaSheng-Kai Liang, Min-Shu Hsieh, Meng-Rui Lee, et al.
International Journal of Antimicrobial Agents|April 11, 2014
Bacteraemia caused by Mycobacterium abscessus subsp. abscessus and M. abscessus subsp. bolletii: clinical features and susceptibilities of the isolatesMeng-Rui Lee, Jen-Chung Ko, Sheng-Kai Liang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 23, 2009
The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cellsJen-Chung Ko, Lyu-Han Wang, Jhih-Yuan Jhan, et al.
Cancer Medicine|June 23, 2017
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in TaiwanChia-Hao Chang, Chih-Hsin Lee, Jen-Chung Ko, et al.
Toxicology Research|June 5, 2019
Capsaicin enhances erlotinib-induced cytotoxicity <i>via</i> AKT inactivation and excision repair cross-complementary 1 (ERCC1) down-regulation in human lung cancer cellsJyh-Cheng Chen, Jen-Chung Ko, Ting-Chuan Yen, et al.
Biochemical Pharmacology|December 21, 2010
Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabineJen-Chung Ko, Min-Shao Tsai, Ya-Hsun Kuo, et al.
BMC Cancer|November 9, 2016
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cellsChun-Hao Pan, Ying-Fang Chang, Ming-Shuo Lee, et al.
Biochemical Pharmacology|October 6, 2009
Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cellsJen-Chung Ko, Ying-Jhen Su, Szu-Ting Lin, et al.
Pharmacology|November 17, 2020
Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer CellsJyh-Cheng Chen, Jen-Chung Ko, Yong-Cing Taso, et al.
Biochemical Pharmacology|February 28, 2016
Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cellsJen-Chung Ko, Jyh-Cheng Chen, Tai-Jing Wang, et al.
Pageof 6